BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 22830613)

  • 21. Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells.
    Hao JH; Yu M; Liu FT; Newland AC; Jia L
    Cancer Res; 2004 May; 64(10):3607-16. PubMed ID: 15150119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway.
    Premkumar DR; Jane EP; Foster KA; Pollack IF
    J Pharmacol Exp Ther; 2013 Aug; 346(2):201-10. PubMed ID: 23740602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.
    Rosato RR; Almenara JA; Maggio SC; Atadja P; Craig R; Vrana J; Dent P; Grant S
    Mol Cancer Ther; 2005 Nov; 4(11):1772-85. PubMed ID: 16275999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.
    Shankar S; Singh TR; Fandy TE; Luetrakul T; Ross DD; Srivastava RK
    Int J Mol Med; 2005 Dec; 16(6):1125-38. PubMed ID: 16273296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ectopic expression of Bcl-2 and Bcl-xL inhibits apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) through suppression of caspases-8, 7, and 3 and BID cleavage in human acute myelogenous leukemia cell line HL-60.
    Lamothe B; Aggarwal BB
    J Interferon Cytokine Res; 2002 Feb; 22(2):269-79. PubMed ID: 11911810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes mitochondrial dysfunction and apoptosis induced by 7-hydroxystaurosporine and mitogen-activated protein kinase kinase inhibitors in human leukemia cells that ectopically express Bcl-2 and Bcl-xL.
    Dai Y; Dent P; Grant S
    Mol Pharmacol; 2003 Dec; 64(6):1402-9. PubMed ID: 14645670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Linarin sensitizes tumor necrosis factor-related apoptosis (TRAIL)-induced ligand-triggered apoptosis in human glioma cells and in xenograft nude mice.
    Xu ZF; Sun XK; Lan Y; Han C; Zhang YD; Chen G
    Biomed Pharmacother; 2017 Nov; 95():1607-1618. PubMed ID: 28950661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
    Sung ES; Park KJ; Choi HJ; Kim CH; Kim YS
    Exp Cell Res; 2012 Aug; 318(13):1564-76. PubMed ID: 22513214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.
    Unterkircher T; Cristofanon S; Vellanki SH; Nonnenmacher L; Karpel-Massler G; Wirtz CR; Debatin KM; Fulda S
    Clin Cancer Res; 2011 Jun; 17(12):4019-30. PubMed ID: 21525171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas.
    Herr I; Ucur E; Herzer K; Okouoyo S; Ridder R; Krammer PH; von Knebel Doeberitz M; Debatin KM
    Cancer Res; 2003 Jun; 63(12):3112-20. PubMed ID: 12810637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.
    El Fajoui Z; Toscano F; Jacquemin G; Abello J; Scoazec JY; Micheau O; Saurin JC
    Gastroenterology; 2011 Aug; 141(2):663-73. PubMed ID: 21683075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects.
    Baader E; Toloczko A; Fuchs U; Schmid I; Beltinger C; Ehrhardt H; Debatin KM; Jeremias I
    Cancer Res; 2005 Sep; 65(17):7888-95. PubMed ID: 16140959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells.
    Gillespie S; Borrow J; Zhang XD; Hersey P
    Apoptosis; 2006 Dec; 11(12):2251-65. PubMed ID: 17051334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential involvement of Bax and Bak in TRAIL-mediated apoptosis of leukemic T cells.
    Han J; Goldstein LA; Gastman BR; Rabinovitz A; Wang GQ; Fang B; Rabinowich H
    Leukemia; 2004 Oct; 18(10):1671-80. PubMed ID: 15356645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways.
    Suliman A; Lam A; Datta R; Srivastava RK
    Oncogene; 2001 Apr; 20(17):2122-33. PubMed ID: 11360196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
    Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
    Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells.
    Walczak H; Bouchon A; Stahl H; Krammer PH
    Cancer Res; 2000 Jun; 60(11):3051-7. PubMed ID: 10850456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Recombinant Circularly Permuted Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) (Recombinant Mutant Human TRAIL) in Combination with 5-Fluorouracil in Human Colorectal Cancer Cell Lines HCT116 and SW480.
    Sun T; Zhu T; Liang X; Yang S; Zhao R
    Med Sci Monit; 2018 Apr; 24():2550-2561. PubMed ID: 29695684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma.
    Gillissen B; Wendt J; Richter A; Richter A; Müer A; Overkamp T; Gebhardt N; Preissner R; Belka C; Dörken B; Daniel PT
    J Cell Biol; 2010 Mar; 188(6):851-62. PubMed ID: 20308427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A caspase-8-independent component in TRAIL/Apo-2L-induced cell death in human rhabdomyosarcoma cells.
    Petak I; Vernes R; Szucs KS; Anozie M; Izeradjene K; Douglas L; Tillman DM; Phillips DC; Houghton JA
    Cell Death Differ; 2003 Jun; 10(6):729-39. PubMed ID: 12761581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.